• Fulfilling

    Potential

    With the Science of Enzymes

  • Fulfilling

    Potential

    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping

    Patients

    Fulfill Their Potential

News & Media

Alcresta Therapeutics Receives New Innovative Technology Contract from Vizient, Inc. For RELiZORB® (iMMOBILIZED LIPASE) Cartridge

Sep 20, 2017

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc. announced RELiZORB has received an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country. The awarded contract, effective Sept. 1, 2017, was based on a recommendation of RELiZORB by hospital members who serve on one of Vizient’s member-led councils.

Alcresta Therapeutics Announces Positive Results, RELiZORB® Increased Fat Absorption in Both Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

Jul 31, 2017

RELiZORB significantly increased plasma levels of omega-3 fatty acids and patients reported a decrease in the frequency of gastrointestinal symptoms in a Pivotal Clinical Trial

Alcresta Therapeutics Receives 510(K) Clearance For Use of RELiZORB® in Children

Jul 20, 2017

RELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children Suffering
From Fat Malabsorption